1. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
- Author
-
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, and Fesik SW
- Subjects
- Animals, Antineoplastic Agents chemistry, Bcl-2-Like Protein 11 metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Drug Design, Drug Discovery, Humans, Immunoprecipitation, Membrane Potential, Mitochondrial drug effects, Mice, Myeloid Cell Leukemia Sequence 1 Protein metabolism, bcl-X Protein metabolism, Antineoplastic Agents pharmacology, Myeloid Cell Leukemia Sequence 1 Protein antagonists & inhibitors
- Abstract
Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic member of the Bcl-2 family of proteins that when overexpressed is associated with high tumor grade, poor survival, and resistance to chemotherapy. Mcl-1 is amplified in many human cancers, and knockdown of Mcl-1 using RNAi can lead to apoptosis. Thus, Mcl-1 is a promising cancer target. Here, we describe the discovery of picomolar Mcl-1 inhibitors that cause caspase activation, mitochondrial depolarization, and selective growth inhibition. These compounds represent valuable tools to study the role of Mcl-1 in cancer and serve as useful starting points for the discovery of clinically useful Mcl-1 inhibitors., Pdb Id Codes: Comp. 2: 5IEZ; Comp. 5: 5IF4., (© 2016 Federation of European Biochemical Societies.)
- Published
- 2017
- Full Text
- View/download PDF